Galper Sharon, Blood Emily, Gelman Rebecca, Abner Anthony, Recht Abram, Kohli Anita, Wong Julia S, Smith Darrell, Bellon Jennifer, Connolly James, Schnitt Stuart, Winer Eric, Silver Barbara, Harris Jay R
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA 02115, USA.
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):348-57. doi: 10.1016/j.ijrobp.2004.06.011.
To determine the long-term prognosis of patients who develop a local recurrence (LR) after conservative surgery (CS) and radiation therapy (RT) for early-stage invasive breast cancer.
Between 1970 and 1987, 2102 patients with clinical Stage I-II breast cancer were treated with CS+RT. LR was defined as any recurrence within the ipsilateral breast with or without simultaneous regional nodal or distant metastasis. Patients were at risk for a LR until the first of distant metastases, second nonbreast malignancy, or death (DF/S/D). The final study population comprised 341 patients with LR. The median time to LR was 72 months. The median follow-up time after LR was 85 months. A proportional hazards model of time from LR to DF/S/D was done to investigate the influence of factors at initial diagnosis and at LR on subsequent outcome.
The actuarial freedom from DF/S/D 5 years after LR was 65% and the survival was 81%. Variables significantly associated with time to DF/S/D were: LR histology (invasive vs. ductal carcinoma in situ, hazard ratio [HR] = 4.1, p < 0.0001); local therapy for LR (none vs. mastectomy or unknown, HR = 3.2, p < 0.0001; and CS +/- RT vs. mastectomy or unknown, HR = 2.0, p = 0.02); time to LR (< or =2 years vs. >5 years, HR = 2.6, p < 0.0001; and 2-5 years vs. >5 years, HR = 1.8, p = 0.006); and age at initial diagnosis (> or =60 vs. <60, HR = 1.6, p = 0.01).
Many patients with LR after CS+RT have prolonged distant disease-free survival, particularly those able to be treated with mastectomy. Patients with a noninvasive LR, longer interval to LR, or age <60 had a longer time to distant failure, second malignancy, or death than other patients.
确定早期浸润性乳腺癌患者在接受保乳手术(CS)和放射治疗(RT)后出现局部复发(LR)的长期预后。
1970年至1987年间,2102例临床I-II期乳腺癌患者接受了CS+RT治疗。LR定义为同侧乳房内的任何复发,无论是否同时伴有区域淋巴结或远处转移。在出现远处转移、第二种非乳腺恶性肿瘤或死亡(DF/S/D)之前,患者均有发生LR的风险。最终研究人群包括341例发生LR的患者。LR的中位时间为72个月。LR后的中位随访时间为85个月。建立了一个从LR到DF/S/D的时间比例风险模型,以研究初始诊断时和LR时的因素对后续结局的影响。
LR后5年无DF/S/D的精算自由度为65%,生存率为81%。与DF/S/D时间显著相关的变量有:LR组织学类型(浸润性癌与原位导管癌,风险比[HR]=4.1,p<0.0001);LR的局部治疗(无治疗与乳房切除术或未知,HR=3.2,p<0.0001;CS+/-RT与乳房切除术或未知,HR=2.0,p=0.02);LR时间(≤2年与>5年,HR=2.6,p<0.0001;2-5年与>5年,HR=1.8,p=0.006);以及初始诊断时的年龄(≥60岁与<60岁,HR=1.6,p=0.01)。
许多CS+RT后发生LR的患者有较长的无远处疾病生存期,尤其是那些能够接受乳房切除术治疗的患者。LR为非浸润性、LR间隔时间较长或年龄<60岁的患者,与其他患者相比,出现远处复发、第二种恶性肿瘤或死亡的时间更长。